Abstract: Diabetes mellitus is characterized by a lack of insulin causing elevated blood glucose, often with associated insulin resistance. Over time, especially in genetically susceptible individuals, such chronic hyperglycemia can cause tissue injury. One pathological response to tissue injury is the development of fi brosis, which involves predominant extracellular matrix (ECM) accumulation. The main factors that regulate ECM in diabetes are thought to be pro-sclerotic cytokines and protease/anti-protease systems. This review will examine the key markers and regulators of tissue fi brosis in diabetes and whether their levels in biological fl uids may have clinical utility.
Introduction
Fibrosis is characterized by extracellular matrix (ECM) accumulation and often by a change in the quality of the ECM, as well as angiogenesis. It is a common pathological response to tissue insults such as hyperglycemia, dyslipidemia, and hypertension. This review will examine the extent and type of tissue fi brosis that occurs in experimental and human diabetes, with an emphasis on potential circulating and urinary predictors and markers of fi brosis in human diabetes. While the pathogenesis and nature of end-organ complications in type 1 and type 2 diabetes are similar, especially in glucose-dependent aspects of microvascular disease, where possible throughout the text the type of diabetes is referenced.
Fibrosis in tissues affected by diabetic complications Microvessels
Long-standing diabetes leads to both structural and functional anomalies in the vasculature (Zimmet 2000; Khan et al 2003) which characterize micro-and macrovascular diabetic complications: retinopathy, nephropathy, cardiomyopathy, peripheral vascular disease, cerebrovascular disorders, and atherosclerosis. Firstly described by Siperstein and colleagues (1968) , extracellular matrix (ECM) alterations and basement membrane (BM) thickening have been documented as structural hallmarks in all target organs of diabetic complications (Brownlee et al 1979; Tsilibary 2003) . The morphological and biochemical disturbances of the ECM are directly related to a loss of function in target organs (Farquhar et al 1972; Scheinman et al 1974; Ikeda et al 1991; Makino et al 1993) . ECM comprises an insoluble network of collagens, elastins, structural glycoproteins, proteoglycans-hyaluronans and integrins, which provide not only mechanical support for the cells, but also mediate complex interactions between the cells or between cells and the ECM of vascular tissues (Hayden et al 2005) . EC matrices differ qualitatively and quantitatively from tissue to tissue and within various organs. Ban and Twigg 
Diabetic retinopathy
Expansion of ECM that occurs in diabetic complications can be due to increased synthesis of matrix proteins and/or an inhibition of ECM degradation. With respect to the increased synthesis of matrix, proteins that are normally present in these structures or proteins that are not present in normal tissue, or both, may be induced. Thus, collagen types I and IV as well as laminin and fi bronectin are normal constituents of normal retinal vessels from large thick-walled vessels down to microvessels less than 10 microns in diameter, whilst types III and V collagen were seen to stain primarily the walls of the larger vessels. A preclinical hallmark of early diabetic retinopathy (DR) is the thickening of the capillary basement membrane (BM) resulting from increased production and/or decreased breakdown of collagen IV, laminin, fi bronectin, and other proteins (Roy et al 1990; Ljubimov et al 1996; Spirin et al 1999; Lorenzi et al 2001) . In proliferative diabetic retinopathy (PDR), the BM of the new vessels and the epiretinal membranes show signifi cantly increased amounts of types VI, VIII, XII, and XIV collagen, as well as perlecan, bamacan (Ljubimov et al 1996) , fi bronectin, tenascin (Ioachim et al 2005) , and vimentin (Hosoda et al 1993) . While not present in normal retina (Jerdan et al 1986) , type II collagen was found in epiretinal membranes (ERM) (Hosoda et al 1993) . A positive relationship was found between fi bronectin expression and ERM proliferative activity (Ioachim et al 2005) . Downregulation of fi bronectin synthesis could partially prevent retinal BM thickening along with a reduction of pericyte loss and acellular capillaries in animal model (Roy et al 2003) .
Diabetic renal disease
Type IV collagen collagen, fi bronectin and laminin, which are normal constituents of the mesangium and glomerular basement membrane (GBM), are increased in diabetic kidney disease (Kim et al 1991; Makino et al 1993; Kiryu et al 1994; Zhu et al 1994; Yagame et al 1995; Razzaque et al 1997; Moriya et al 2001) . Accelerated matrix deposition (type IV collagen) can be present even in early stages of diabetic renal disease (microalbuminuria stages) in experimental models (Liu Y et al 2007) . In diabetic diffuse glomerulosclerosis deposition of collagen IV, V, laminin, and fi bronectin is increased in the mesangial matrix and glomerular basement membranes (Nerlich et al 1991; Tsilibary 2003) , whilst in nodular glomerulosclerosis normal BM components are decreased or absent (Olgemoller et al 1993) . Expressed only under pathological conditions, type I and III collagen appears in the late stages of glomerulosclerosis (Glick et al 1992; Makino et al 1994; Razzaque et al 1994; Makino et al 1995; Stokes et al 2000; Schaefer et al 2001) , and are associated with the development of Kimmelstiel-Wilson nodules rather than with the diffuse expansion of the mesangial matrix, which occurs in the early and moderately advanced stages of the disease. Decreased levels of proteoglycans (heparin sulphate, perlecan) found in diabetic kidney in the mesangial matrix, GBM, the endothelial and epithelial BM, and renal tubular cells have also been assigned a role in the development of diabetic micro-and macroalbuminuria (Schaefer et al 2001) . Interestingly, a substantial subset of type 2 diabetic patients, despite the presence of microalbuminuria or proteinuria, have normal glomerular structure with or without tubulointerstitial and/or arteriolar abnormalities (Fioretto et al 2007) .
Diabetic cardiomyopathy
Both types I and III collagen are present in normal and diseased myocardial tissue. Type I collagen is predominant in the myocardium, but type III is more specifi c to cardiac tissue (Bishop et al 1995; Zannad et al 2000; D'Armiento 2002) . Myocardial biopsies from diabetic subjects revealed a signifi cantly higher proportion of type III collagen compared with their nondiabetic counterparts, while the proportion of collagen type I did not differ between the groups (Shimizu et al 1993) . Responsible for the increased left ventricle (LV) mass (van Hoeven et al 1990) , diffuse myocardial fi brosis has a distribution in both interstitium and perivascular sites (Regan et al 1977; Nunoda et al 1985; Genda et al 1986; Das et al 1987; van Hoeven and Factor 1990) . Extensive myocyte necrosis and replacement of contractile fi bers by connective tissue are likely to account for depressed cardiac performance, at least in advanced stages of diabetic cardiomyopathy (Factor et al 1980) . It appears that hypertrophy of myocardial cells and myocardial interstitial fi brosis may be present even in mild hyperglycemia in diabetes (Nunoda et al 1985) .
Larger arteries
In animal models of type 2 diabetes it has been found that increased intimal proliferation and medial thickness as well as ECM deposition occur in vessels such as mesenteric arteries and aorta (Song and Ergul 2006) . Vascular remodeling and hypertrophy associated with augmented expression of dedifferentiation markers of vascular smooth muscle cells also occur in larger vessels like aorta (Vranes et al 1999) . Fibronectin expression varied in different reports in large vessels (Fukuda et al 2005) . Proteoglycans (PGs) such Fibrosis markers in diabetic complications as versican, biglycan, and decorin have been involved in diabetic nephropathy pathogenesis (Schaefer et al 2001) . PGs accumulate in developing atherosclerotic and restenotic lesions, and thus contribute to plaque burden and infl uence cellular and extracellular events associated with the pathogenesis of vascular lesions, such as migration and proliferation, lipid metabolism and retention, and thrombosis (Shirk et al 2000; Edwards et al 2004; Nakashima et al 2007; Tran et al 2007) .
Nonalcoholic fatty liver disease
Type 2 diabetic patients also have an increased risk for developing chronic liver disease. Nonalcoholic fatty liver disease (NAFLD) represents a spectrum of conditions characterized histologically by excessive accumulation of hepatic fat in the absence of alcohol consumption. Obesity, type 2 diabetes, dyslipidemia, and hypertension contribute to the risk for liver disease and to disease progression. Two main histological patterns of NAFLD are described: fatty liver alone and nonalcoholic steatohepatitis (NASH). NASH is an increasingly recognized cause of liver-related morbidity and mortality (Angulo 2002; Sanyal 2002; Charlton 2004) , with about a quarter of patients progressing to serious liver sequelae, including end-stage liver disease and hepatocellular carcinoma (Bugianesi et al 2002; Ratziu et al 2002) . Those at highest risk include patients with signifi cant hepatic necroinfl ammation and fi brosis (Ratziu et al 2000; Sanyal 2002 ).
Unlike other vascular beds, the normal hepatic sinusoids have no BM to become thickened. Sinusoidal (perisinusoidal) fi brosis with formation of BMs occurs in a variety of liver diseases, including chronic viral hepatitis, alcoholic hepatitis and NASH. In those diseases, the fi brosis is a result of the activation of the hepatic stellate cells with a phenotypic transition to collagen-producing myofi broblasts. Activated hepatic stellate cells are involved in the ECM degradation and remodeling that occur with fi brogenesis (Sugimoto et al 2005) .
Effects of diabetes on regulators of ECM turnover
Metabolic and hemodynamic induction of fi brosis by hyperglycemia Chronic hyperglycemia is a main factor in the onset of microvascular diabetic complications in both type 1 and 2 diabetes, as strict glycemic control reduces end-organ complication incidence and rate of progression (The Diabetes Control and Complications Trial Research Group 1993; UK Prospective Diabetes Study Group 1998) . This pathogenesis is shown schematically in Figure 1 . Specifi c biochemical pathways linking hyperglycemia to microvascular changes have been proposed: increased glucose fl ux through the polyol pathway (Greene et al 1987) , nonenzymatic glycation of proteins (Brownlee et al 1988) , glucose autooxidation, and oxidative stress (Hunt et al 1990) , hyperglycemic pseudohypoxia Elevated blood glucose levels (to diabetic range)
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Initial insult(s) (genetic and environmental) Cell and tissue injury Figure 1 The linear pathway leading from insulin defi ciency, through hyperglycemia to diabetes complications.
Ban and Twigg (Williamson et al 1993) , enhanced activation of protein kinase C isoforms (Lee et al 1989; DeRubertis and Craven 1994) , and alteration in cell signaling pathways (Brownlee 2001; Sheetz et al 2002) . As described in subsequent sections, experimental data support causative roles for hyperglycemia and these downstream biochemical pathways in causing alterations in ECM turn-over (Fukui et al 1992; Nahman et al 1992; Roy et al 1994; Wahab et al 1996) . Hyperglycemia can work through both metabolic and hemodynamic pathways to change growth factors and ECM turn-over. This is shown schematically in Figure 2 .
Advanced glycation end-products (AGEs)
Hyperglycemia is responsible for the presence of high levels of nonenzymatically produced AGEs in patients with diabetes (Goldin et al 2006) . AGEs are able to stimulate directly the production of ECM. Nonenzymatic glycosylation of collagens produces cross-linkages and hence may produce physical alterations in the properties of the ECM. AGEs modifi cation of matrix proteins is able to disrupt matrixmatrix and matrix-cell interactions, contributing to their profi brotic action. In addition, AGEs signifi cantly interact with the renin-angiotensin system. AGEs play important roles in cell signaling by interacting with specifi c receptors, receptor for advanced glycation end products (RAGE) , that link to the activation of adhesion molecules, proinfl ammatory cytokines and growth factors, thus contributing to the pathogenesis of diabetic complications McLennan et al 2004) . AGEs have extracellular effects, such as protein cross-linking, that appear to inhibit ECM degradation and promote the expansion of the glomerular mesangial matrix and BM in diabetic kidney disease. Drugs that either inhibit the formation of AGE or break AGEinduced cross-links have been shown to be renoprotective in experimental models of diabetic nephropathy (Forbes et al 2002) .
The renin-angiotensin-aldosterone system
The renin-angiotensin-aldosterone system (RAAS) is an important contributor to the pathogenesis of diabetic microand macrovascular complications by inducing various tissue responses, such as vasoconstriction, infl ammation, oxidative stress, cell hypertrophy and proliferation, angiogenesis and fi brosis. RAAS effects can be locally generated in many organs (Paul et al 1993; Morgan et al 1994; Wagner et al 1996; Engeli et al 1999; Bataller et al 2003) .
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Angiotensin II (Ang II), the main physiological effector molecule of RAAS, mediates fi brosis by stimulating the synthesis of ECM components (Kagami et al 1994; GomezGarre et al 1996; Brilla et al 1997) apoptosis/proliferation (Efrati et al 2007) , infi ltration of infl ammatory cells, and the release of infl ammatory cytokines and growth factors such as transforming growth factor (TGF)-β1 (Wu et al 1997) , monocyte chemoattractant protein (MCP)-1 (Ruiz-Ortega et al 1998), vascular endothelial growth factor (VEGF) (Otani et al 2000) , platelet derived growth factor (PDGF) (Naftilan et al 1989) , and connective tissue growth factor (CTGF) (Ruperez et al 2003a; Finckenberg et al 2003) . Ang II is up-regulated under the diabetic conditions (Singh et al 1999) and exerts its deleterious effects through the angiotensin type I receptor (AT1R). RAS blocking with either angiotensin converting enzyme inhibitors (ACEI) or angiotensin type 1 receptor blockers (ARB) has clearly demonstrated positive outcomes on diabetic complications, with benefi ts beyond those derived from lowering blood pressure. Thus ACEI and/ or ARB treatment can slow the progression of diabetic renal disease (The EUCLID Study Group 1997; Heart Outcomes Prevention Evaluation Study Investigators 2000), decrease cardiovascular events (Heart Outcomes Prevention Evaluation Study Investigators 2000), may decrease retinopathy in T1DM (Chaturvedi et al 1998) and improves diastolic dysfunction in diabetic patients (Kawasaki et al 2007) .
Another component of the RAAS, aldosterone, plays also a role in the development of hypertension, endothelial dysfunction, vascular structure damage, proteinuria, myocardial fi brosis, collagen synthesis (Cha et al 2005) . Spironolactone, an aldosterone antagonist, associated to ACEI and/or ARB treatment may offer additional renoprotection in diabetic nephropathy Schjoedt et al 2006; van den Meiracker et al 2006) .
Growth factors
Under normal circumstances ECM undergoes continuous synthesis and degradation and ECM turn-over is a requisite for normal structure and function of organs and tissues (Tyagi et al 1995) . ECM turn-over is characterized by a balance between matrix formation and matrix degradation. Factors that regulate ECM formation include multiple forms of growth factor such as such as TGF-β (McClain et al 1992; Kolm et al 1996; Riser et al 1998) , CTGF Twigg et al 2001; McLennan et al 2004; Paradis et al 2001; Liu X et al 2007) , and insulin-like growth factor I (IGF-I), fi broblast growth factor (FGF), epidermal growth factor (EGF) and PDGF, (Lembach 1976; Tseng et al 1982; Dresow et al 1984; Roberts et al 1986; Qi et al 2005) . Enzymes responsible for ECM degradation and remodeling include the matrix metalloproteinases (MMPs) (McLennan et al 1998 (McLennan et al , 2000 Death et al 2003) , and serine proteases (Geiger et al 1988) , as well as their respective tissue inhibitors, the TIMPs (Nakamura et al 1994; Shankland et al 1996; Gomez et al 1997) , and PAI-1 (Fisher et al 1997; McLennan et al 2000) . These regulators of ECM will now be explored in detail in diabetic complications.
The important role of growth factors in the pathogenesis of diabetic long-term complications was suggested by their increased concentrations in target tissues (Yamamoto et al 1993; Tikellis et al 2004; Roestenberg et al 2006; Umezono et al 2006) . In diabetic nephropathy, IGF-I seems to be implicated in the earlier stages of the disease, while TGF-β and CTGF are involved both in the early and later stages, being responsible, at least in part, for ECM accumulation (Park et al 1997; Gilbert et al 1998; Riser et al 2000) . VEGF and FGF play a pivotal role both in nonproliferative and proliferative retinopathy (Wells et al 1996; Mathews et al 1997) . Figure 3 indicates the main growth factors involved in diabetic complications, based on tissue levels measured in human and animal diabetes, and also on intervention studies mainly in animals. An excess of growth factor is implicated in tissues where fi brosis predominates, whereas a lack of growth factors occurs in diabetic neuropathy and wound healing.
TGF-β
TGF-β is generally accepted to be the main pro-fi brotic factor in diabetic nephropathy. Several lines of experimental and clinical evidence support a major role for TGF-β in development of glomerulosclerosis and interstitial fi brosis in diabetes. Diabetic environment up-regulated TGF-β1 expression and bioactivity in glomerular mesangial cells and proximal tubule cells (Ziyadeh et al 1994 (Ziyadeh et al , 1998 Sharma et al 1995) . With the development of incipient diabetic nephropathy TGF-β mRNA increased in mesangial cells, podocytes and tubular epithelial cells. Progression to manifest diabetic nephropathy was associated with further increase in TGF-β mRNA, especially in the glomeruli (Wahab et al 2005) . The kidney of a diabetic patient actually elaborates TGF-β1 protein into the circulation whereas the kidney of a nondiabetic subject extracts TGF-β1 from the circulation (Sharma et al 1997) . Inhibition of TGF-β1 with neutralizing antibodies prevented glomerular enlargement, and attenuated the excess matrix expression by reducing type IV collagen and fi bronectin mRNA (Sharma et al 1996; Ziyadeh et al 2000) .
Up-regulation of TGF-β protein was demonstrated in the myocardium of rodents with diabetic cardiomyopathy. ARB treatment reduced its expression and decreased cardiac fi brosis (Westermann et al 2007) . TGF-β is also involved in liver fi brosis (Roth et al 1998) , by activating the hepatic stellate cells and inducing apoptosis of hepatocytes in liver injury (Oberhammer et al 1992) . However, due to its important anti-proliferative and anti-infl ammatory effects, TGF-β is not a suitable target for therapeutic intervention.
CTGF
CTGF is another prominent growth factor in the pathogenesis of diabetic nephropathy. High glucose conditions, TGF-β, AGEs, RAS, TNF-α, mechanical strain or CTGF itself promote CTGF expression by mesangial cells (Wahab et al 1996; Murphy et al 1999; Riser et al 2000; Twigg et al 2001 Twigg et al , 2002a Cooker et al 2007; Hughes et al 2007) . CTGF can also be produced by podocytes (Roestenberg et al 2006) , parietal epithelial cells (Umezono et al 2006) and proximal tubular cells (Wang et al 2001; Roestenberg et al 2006) . In experimental type 1 and type 2 diabetes CTGF mRNA and protein was up-regulated in various organs: kidney, heart, liver, retina (Roestenberg et al 2006) . Glomerular CTGF mRNA levels were found to be upregulated in diabetic patients with microalbuminuria as well as in overt nephropathy (Umezono et al 2006) . In addition, CTGF mRNA levels were found to correlate with the degree of albuminuria (Adler et al 2001) . We have recently found that renal tubular CTGF protein by renal biopsy at 5 years predicts albuminuria at 10 years, in a diabetic baboon model of type 1 diabetes (Thomson et al 2007) . The role of CTGF in DN pathogenesis in both type 1 and type 2 diabetes has been confi rmed by a recent study showing that a CTGF antisense oligonucleotide may attenuate progression of nephropathy in mice (Guha et al 2007) . CTGF overexpression in podocytes was critically involved in diabetes-related GBM thickening (Roestenberg et al 2006) . However, a site-specifi c downregulation of CTGF accompanied by a reduced VEGF-A mRNA in glomeruli from diabetic patients can be evidenced in DN and is a result of podocyte loss (Baelde et al 2007) .
Relative abundance of myocardial mRNA for CTGF compared with brain natriuretic peptide (BNP) was positively correlated with diastolic dysfunction, myocardial fi brosis area, and procollagen type 1 mRNA expression in a rat pressure overload cardiac hypertrophy model. Exogenous BNP prevented the production of CTGF in cardiac myocytes (Koitabashi et al 2007) .
CTGF has been shown to be up-regulated in the retina of diabetic rats (Tikellis et al 2004) . It appears that in diabetes CTGF expression shifts from microglia to microvascular pericytes (Kuiper et al 2004) . CTGF was also expressed in endothelial cells and myofi broblast in PDR membranes, and in myofi broblast in proliferative vitreoretinal membranes (Abu El-Asrar et al 2007) . CTGF is overexpressed in pericytes in the human diabetic retina, irrespective of changes related to clinical DR like vascular leakage (Kuiper et al 2004) . Overexpression of CTGF in cultured human aortic smooth muscle cells, a cell type closely related to pericytes and mesangial cells, induced apoptosis by activating caspase 3 (Hishikawa et al 1999 • Diabetic cardiomyopathy -VEGF Figure 3 The major growth factors implicated in diabetes complications. The prosclerotic ones involved in human diabetic fi brosis are currently thought to be TGF-β and CTGF.
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In fi brotic liver, CTGF mRNA and protein are produced by hepatocytes, fi broblasts, myofi broblasts, hepatic stellate cells (HSCs), endothelial cells, and bile duct epithelial cells (Rachfal et al 2003) . Interestingly, whilst in HSCs CTGF was only marginally stimulated by TGF-β, in cultured hepatocytes it was strongly upregulated by TGF-β (Gressner et al 2007) . CTGF could be reduced in liver by antisense RNA of CTGF recombinant or slicing through siRNA, which decreased activation of HSCs, prevented the upregulation of CTGF and TGF-beta1 gene expression and inhibited accumulation of connective tissue proteins in the liver (George et al 2007; Lu et al 2007) .
Once induced, CTGF can up-regulate its own gene expression (Riser et al 2000; Twigg et al 2001; Wahab et al 2001) . It is also able to initiate changes in ECM composition: it increased expression of fi bronectin (Wahab et al 2001; Ruperez et al 2003a; Weston et al 2003) and enhanced fi bronectin assembly into an insoluble matrix (Weston et al 2003) , increased in type IV (Zhou et al 2004) , type III (Lam et al 2004) and type I collagen production (Gore-Hyer et al 2002), and up-regulated integrins on the cell surface, facilitating the deposition and assembly of ECM proteins (Weston et al 2003) . Furthermore, CTGF caused induction of plasminogen activator inhibitor-1 (Wahab et al 2001) , rearrangement of the actin cytoskeleton (Crean et al 2002) and an increase in TIMP-1 with subsequent decrease in matrix degradation (McLennan et al 2004) . CTGF also exerted a strong chemotactic effect on peripheral blood mononuclear cells in vitro (Cicha et al 2005) , which may then contribute to tissue infl ammation and late fi brosis (Frazier et al 1996) .
CTGF has been described as a downstream mediator of TGF-β in the fi brotic process (Igarashi et al 1993; Grotendorst et al 1996; Duncan et al 1999; Weston et al 2003; Kobayashi et al 2005) . TGF-β1-induced effects can be blocked by CTGF antisense oligonucleotides (Duncan et al 1999; Abdel-Wahab et al 2002; Weston et al 2003) . However, CTGF can also exert its pro-fi brotic effects via TGF-β1-independent pathways (Murphy et al 1999; Blom et al 2001; Twigg et al 2001; McLennan et al 2004; Chaqour et al 2006) as seen for induction of CTGF by AGEs which is TGF-β independent (Twigg et al 2001) . Glucose-induced collagen production was reduced by CTGF anti-sense nucleotide (Wahab et al 2001; Abdel-Wahab et al 2002; Ruperez et al 2003a; Weston et al 2003; Guha et al 2007) , ACEI or ARB (Ruiz-Ortega et al 1995; Wu et al 1997; Border et al 1998; Ruperez et al 2003b; Tsutsui et al 2007) , or by treatment with an AGE inhibitor (Twigg et al 2002b; Candido et al 2003) . CTGF can interact with, and infl uence the signaling of IGF-I (Lam et al 2003) , VEGF (Brigstock 2002) , TGF-β (Grotendorst et al 1996) and bone morphogenic proteins (BMPs) (Abreu et al 2002) . Moreover, CTGF can be cleaved by metalloproteases (MMPs) and other proteases (Hashimoto et al 2002) .
PDGF-β
PDGF-β is involved in structural alterations at the glomerular level. It seems that high glucose induces an early activation of a PDGF loop that in turn causes an increase of TGF-β1 gene expression, thus modulating both human mesangial cell proliferation and mesangial matrix production (Di Paolo et al 1996) .
VEGF VEGF appears to be another mediator for these early and late vascular changes. Neutralizing antibodies directed against VEGF blocked vascular permeability and blood fl ow changes induced by elevated tissue glucose and sorbitol levels in a dosage-dependent manner (de Vriese et al 2001) . VEGF signaling affected GBM thickening, slit pore density, and nephrin quantity, all of which were associated with the extent of diabetic albuminuria. These effects could be blocked by a VEGF receptor inhibition (Sung et al 2006) .
FGF
FGF is secreted by fi broblasts, macrophages and in particular endothelial cells (EC) in response to tissue injury and is important in promotion of neovascularization. Produced and stored in epiretinal membranes (Hueber et al 1996; Schneeberger et al 1997) , FGF is a potent endothelial cell mitogen that has been proposed to play a role in proliferative diabetic retinopathy and other neovascular processes (Hanneken et al 1991) .
Protease systems and their regulators
The MMP system Metalloproteinases (MMPs) are a family of zinc-dependent enzymes with the combined ability to digest all ECM proteines: native and partially degraded fi brillar collagens, basement membrane collagens, proteoglycans, elastin, fi bronectin. The gelatinase (MMP-2 and MMP-9) are two proteinases primarily responsible for breaking down type IV collagen from the BMs. These are produced by multiple vascular cell types, such as pericytes, podocytes, vascular smooth muscles cells, renal mesangial cells, fi broblasts, macrophages. The MMPs are synthesized as inactive zymogens with a pro-peptide domain that must be removed before the enzyme is active. Activation of MMPs can be induced by urokinase type (uPA) and tissue-type (tPA) plasminogen activators that cleave plasminogen into active plasmin. MMP-9, but not other MMPs, is able to upregulate biologically active proteins such as the profi brotic growth factor TGF-β (Rutschow et al 2006) .
A major control point in the regulation of active enzyme is inhibition of the active form by their tissue family of inhibitors. TIMPs comprise a family of four protease inhibitors (TIMP-1 to TIMP-4), which are expressed in a tissue specifi c pattern and regulate the function of MMPs either by inhibiting active MMPs or by controlling their activation process. Overall, all MMPs are inhibited by TIMPs once they are activated, with most of the MMPs being inhibited by TIMP-1. The gelatinases (MMP-2 and MMP-9) can form complexes with TIMPs when the enzymes are in the latent form. The complex of latent MMP-2 (pro-MMP-2) with TIMP-2 serves to facilitate the activation of pro-MMP-2 at the cell surface by MT1-MMP (MMP-14), a membrane-anchored MMP. The role of the pro-MMP-9/TIMP-1 complex is unknown.
An imbalance between MMPs and TIMPs plays an important role in ECM modeling that favors tissue fi brosis. For example, the imbalance between the MMP-2 and TIMP-2, caused primarily by an increase in TIMP-2 activity, may contribute to the pathogenesis of diabetic nephropathy (Han et al 2006) . Decreased MMP-2 expression and activity, and up-regulated MMP-9 protein were found in the myocardium of diabetic mice with STZ-induced DCM. These alterations were corrected by ARB treatment (Westermann et al 2007) . Myofi broblasts and vascular endothelial cells in PDR membranes expressed an increase in MMP-9 protein and activity (Abu El-Asrar et al 2007). ProMMP-9 and activated MMP-9 levels were also signifi cantly increased in vitreous samples in PDR patients. In addition, TIMP-1 levels were signifi cantly increased in PDR patients. Activated MMP-9 levels in vitreous samples of PDR patients with hemorrhage were higher than those in PDR patients without hemorrhage, suggesting that activated MMP-9 might be involved in hemorrhagic transformation in these patients (Descamps et al 2006) .
The plasminogen system
Plasminogen activator (PA)/plasmin/PA inhibitor (PAI) system is involved in ECM degradation. PAI-1 may promote ECM build-up by preventing plasmin and MMPs activation (McLennan et al 2000) . PAI-1 can regulate TGF-beta expression by binding to uPAR and activating the extracellularregulated signal kinase (ERK)/MAPK pathway (Yang et al 2007) . PAI-1 plays a critical role in ECM remodeling in the kidney. Normal human kidneys do not express PAI-1 but PAI-1 is overexpressed in pathologic conditions associated with renal fi brosis including diabetic nephropathy (Paueksakon et al 2002; Hagiwara et al 2003) . Reactive oxygen species mediate PAI-1 up-regulation in renal cells cultured under high glucose, hypoxia, and with TGF-beta1 (Lee and Ha 2005) . PAI-1 induced ECM deposition in diabetic kidney through increased ECM synthesis by TGF-beta1 up-regulation as well as through decreased ECM degradation by suppression of plasmin and MMP-2 activity (Lee and Ha 2005) . Impaired fi brinolysis resulting from high plasma PAI-1 can lead to excessive fi brin accumulation within vessels, resulting in atherothrombosis. Increased expression of PAI-1 was found in the arterial wall in patients with type 2 diabetes (Pandolfi et al 2001) . This increased vascular expression of PAI-1 promotes neointima formation via accumulation of fi brin or fi brinogen as a result of inhibited clearance of platelet-fi brin thrombi. PAI-1, an acute phase protein, also has been involved in vascular infl ammation (Alessi et al 2004) . Figure 4 shows methods in diabetes by which pro-fi brotic growth factors may link with the protease and anti-protease systems to dysregulate ECM turnover and thus cause ECM accumulation.
Endothelin-1
Endothelin-1 (ET-1) is a potent vasoconstrictor peptide, which can also exert pro-infl ammatory, mitogenic and profi brotic effects. Up-regulated by glucose, angiotensin II, TGF-β, ROS and PDGF in various renal cells (Zoja et al 1991; Kohno et al 1992; Kohno et al 1993; Hughes et al 1996; Hua et al 2001) , retinal cells (Chakravarthy et al 1997; Park et al 2000; Yokota et al 2003) and cardiomyocytes, ET-1 has been linked with matrix accumulation in diabetic kidney (Ruiz-Ortega et al 1994; Hargrove et al 2000) and cardiomyocyte hypertrophy (Chen et al 2007) , and with hemodynamic and histopathological abnormalities in diabetic retina (Bursell et al 1995; Takagi et al 1996; Chakrabarti et al 1998) . Neutralizing ET-antibodies and anti-sense oligonucleotides, as well as ET-receptor antagonist treatment reduced proteinuria and the production of ECM proteins in the kidney (Li et al 1999; Hocher et al 2001; Sugimoto et al 2002) and prevented myocardial and coronary dysfunction (Ding et al 2006; Wolkart et al 2006) in experimental diabetes.
Markers of fi brosis in biological fl uids in diabetes
In order to assess accurately the morphological changes in the target organs and the extent to which the fi brotic changes Fibrosis markers in diabetic complications affect their function, invasive studies (tissue biopsy) is commonly required. However, biopsy is not always feasible in human tissues and is associated with obvious risks. Therefore it is highly desirable to potentially estimate the severity of organ fi brosis by measuring ECM factors in biological fl uids (peripheral blood or urine). Such markers, if proven they mirror the changes in specifi c organs structure and function, will allow a better monitoring of the disease. Moreover, if these markers levels show changes with treatment, they will be a useful tool to evaluate the therapeutic interventions. Thus the potential clinical value of the circulating or urinary levels of several ECM components and its regulators have been tested in diabetes and its complications.
ECM formation and degradation markers
Serum aminoterminal propeptide of type III (PIIINP) or type I (PINP) procollagen and carboxyterminal propeptide of type I procollagen (PICP) are released in a stoichiometric manner with collagen type III or I molecules during collagen biosynthesis, and therefore they are considered markers of the synthesis and deposition of type III and I collagen (Jensen et al 1990; Risteli et al 1995; Weber 1997) . However, there is evidence that some of the PIIINP is also released during collagen degradation, because these propeptides are not completely cleaved during collagen synthesis (Fleischmajer et al 1985) . Therefore, PIIINP could refl ect both synthesis and degradation of collagen.
Circulating levels of collagen have been suggested as indicators of diabetic complications. Elevated serum levels of both PIIINP and laminin were associated with the development of diabetic microangiopathy (Okazaki et al 1988) . Another study (Migdalis et al 1994) found elevated serum PIIINP levels in type 2 diabetic subjects with peripheral vascular disease and proposed that this refl ected an increase in collagen deposition in the large arteries that accompanies the development of macroangiopathy. Serum PIIINP was also increased in type 2 diabetic patients with nephropathy (Ishimura et al 1996) .
PICP concentration did not differ between uncomplicated type 2 diabetic patients and controls, but it was increased in complicated diabetes and related to the progression of nephropathy (Inukai et al 2000) . In contrast, other investigators 
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found decreased levels of serum PICP but increased PIIINP concentrations in subjects with proliferative retinopathy compared with those with no retinopathy (Arkkila et al 2001) . Similarly, hypertensive type 2 diabetic patients had higher mean levels of PIIINP than controls, and lower mean levels of PINP and PICP (Alla et al 2006) . No association between collagen markers and neuropathy was found (Arkkila et al 2001) .
ECM regulators as systemic fi brosis markers
In patients with type 1 diabetes plasma and urinary TGF-β1 levels were signifi cantly higher than in controls. The effect of metabolic control on plasma TGF-β level is controversial (Azar et al 2000; Flores et al 2004; Thrailkill et al 2007) . Increased TGF-β levels in both plama and urine were found especially in relation to diabetic nephropathy (Pfeiffer et al 1996; Houlihan et al 2002) . Urinary TGF-beta signifi cantly decreased with ACEI, ARB or thiazolinediones treatment, in parallel with a decrease in albuminuria (Matos et al 2005; Katavetin et al 2006; Woo et al 2006) .
While it seems correlated with glycemic control (Kakizawa et al 2004) , plasma VEGF concentration was not strongly correlated with risk factor status or microvascular disease in type 1 diabetes, nor was affected by ACE inhibition (Chaturvedi et al 2001) . Urinary VEGF concentrations were signifi cantly higher in the diabetic groups, even at the normoalbuminuric stage, with further increase as diabetic nephropathy advanced (Kim et al 2004) .
Diabetes status is associated with dysregulation in the circulating MMP/TIMP system even in the absence of complications. Thus, serum MMP-9 and TIMP-1 levels are increased in both type 1 (Maxwell et al 2001) and type 2 diabetes (Tayebjee et al 2004) , with no changes in MMP-2 concentration. In contrast, in another study urine and plasma MMP-2 levels and plasma MMP-2 activity were all significantly elevated in type 1 diabetic patients, with urine MMP-2 correlated with higher HbA1c, longer duration of diabetes, evidence of renal hyperfi ltration and the presence of microalbuminuria (Thrailkill et al 2007) . Increased serum MMP-2 and TIMP-1 concentrations, but no elevation of MMP-9 levels, were also found in a cohort of diabetic patients with mild or no complications .
Some therapies have been proven effi cient in reduction the plasma/serum MMPs and TIMP-1 levels in diabetic patients. Thiazolidinediones, which act via the PPARγ receptor, reduced the increase in circulating levels of MMP-9 but had no effect on circulating MMP-2. Furthermore, reductions in MMP-9 levels were associated with decrease in other infl ammatory markers, such as C-reactive protein, PAI-1, IL-6, TNF-α and serum amyloid A (Haffner et al 2002; Marx et al 2003; Hanefeld et al 2007) .
Circulating MMP-9 and TIMP-1 could also be reduced by lipid reduction therapy (plasma LDL apheresis) in diabetic patients with end-stage renal disease and arteriosclerosis obliterans (Nakamura et al 2003) . Multifactorial cardiovascular risk reduction therapy with intensive glucose control and statin therapy caused signifi cant reductions in circulating TIMP-1 levels (Tayebjee et al 2004) . This effect was probably independent of blood pressure lowering, as the latter was relatively well controlled from the outset and did not fall signifi cantly.
Current evidence for clinical utility of markers of fi brosis in diabetes Diabetic renal disease
Type IV collagen in the circulation or urine has been identifi ed as a possible indicator of renal injuries, especially in early stages of diabetic nephropathy, in numerous, albeit relatively small studies (Watanabe et al 1991; Kotajima et al 2000; Xu et al 2002; Tashiro et al 2004) . Both serum and urinary type IV collagen increased in accordance with the clinical stage of the renal disease (Watanabe et al 1991 (Watanabe et al , 2000 Xu et al 2002; Tashiro et al 2004) . Serum carboxy-terminal propeptide type I procollagen (P1CP) levels may also refl ect the progression of diabetic nephropathy in patients with type 2 diabetes (Inukai et al 2000) . In type 1 diabetes, measurement of syndecan-1 in serum has shown signifi cant increase even at the microalbuminuric stage compared to normoalbuminuric patients (Svennevig et al 2006) . TGF-β levels in serum were increased in patients with diabetic nephropathy (Sharma et al 1999) and decreased with ACEI (Ellis et al 1998; Sharma et al 1999) .
Urinary levels of collagen IV positively correlated with uPA, and that of fi bronectin negatively correlated with PAI-1 in the diabetic patients with microalbuminuria (Woo et al 2006) . Urinary TGF-β was signifi cantly increased in type 2 diabetic patients with micro-or macroalbuminuria. ACEI, ARB, and TZD signifi cantly reduced urinary excretion of TGF-β in these patients (Houlihan et al 2002; Praga et al 2003; Matos et al 2005; Katavetin et al 2006; Woo et al 2006) .
Increasing evidence has emerged on circulating and urinary CTGF as indicators of renal disease in diabetes. Elevated plasma CTGF concentrations have been found in diabetic nephropathy. CTGF levels in the circulation correlated with Fibrosis markers in diabetic complications urinary albumin excretion, creatinine clearance, glycemic control and duration of diabetes (Roestenberg et al 2004) . Of note, there was a wide overlap in plasma CTGF between normoalbuminuric patients and those with diabetic nephropathy. Urinary concentrations of CTGF (U-CTGF) has been more extensively investigated than circulating CTGF, in diabetic renal disease (Gilbert et al 2003; Riser et al 2003; Nguyen et al 2006) . U-CTGF was correlated with clinical markers of renal disease severity (urinary albumin excretion rate and glomerular fi ltration rate). Furthermore, the association of U-CTGF with diabetic nephropathy was comparable with that of the established risk factors: HbA1c and systemic blood pressure. Signifi cantly higher in patients with microalbuminuria or overt nephropathy, urinary CTGF excretion varied largely across the studies, from 1.6-fold (Nguyen et al 2006) to 6-fold (Riser et al 2003) and were 10-100-fold higher (Gilbert et al 2003) in diabetic nephropathy versus normoalbuminuric subjects. Large overlaps in U-CTGF were also noted between patients and controls (Nguyen et al 2006) . In patients with DN, U-CTGF correlated positively with urinary albumin excretion and negatively with GFR (Nguyen et al 2006) . It is unclear to what extent plasma CTGF levels contribute to U-CTGF. CTGF and its fragments are predicted to be cleared from plasma by glomerular fi ltration.
Animal studies have shown increased CTGF mRNA in renal cortex in a very early phase of nephropathy, which paralleled an increase in plasma and U-CTGF (Roestenberg et al 2006) . Local production of CTGF in the kidney, renal fi ltration of (elevated) plasma CTGF, together with tubular dysfunction and/or saturation of tubular reabsorption capacity in proteinuric patients may all be involved in increased U-CTGF (Nguyen et al 2006) . Interventional studies have shown that in type 1 diabetes with nephropathy, RAS blockade with ARB signifi cantly decreased U-CTGF concentration, and this reduction was associated with a slower rate of decline in GFR in a cohort of hypertensive type 1 diabetic patients with diabetic kidney disease (Andersen et al 2005) . However, plasma CTGF remained unchanged throughout the study, suggesting that circulating CTGF is at least partly independent of U-CTGF and renal dysfunction.
In diabetic patients, plasma VEGF levels were found to be positively correlated with plasma urea and urinary ACR, and urinary VEGF was positively correlated with urinary ACR and creatinine. Urinary VEGF and serum creatinine were independently correlated with urinary ACR (Kim et al 2004) . Urinary excretion of VEGF increased during the earlier stage of diabetic nephropathy and was signifi cantly correlated with urinary albumin excretion. This suggests that urinary VEGF might be used as a sensitive marker of diabetic nephropathy and for predicting disease progression (Kim et al 2004) . In addition, another study implicated the potential of plasma VEGF as a DN marker (Baba et al 2004) .
Dysregulations in circulating and urinary MMP/TIMP systems have been found in diabetic renal disease. Thus, increased levels of plasma MMP-9 have been shown in DN patients (Nakamura et al 2000; Zaoui et al 2000) , and were signifi cantly reduced by ACEI treatment (Nakamura et al 2000) . Moreover, it seems that elevation in plasma MMP-9 may precede the onset of microalbuminuria in type 2 diabetic patients (Ebihara et al 1998) . Higher levels of MMP-9 were also found in the urine of type 2 diabetic patients with macroalbuminuria (Tashiro et al 2004) . Interestingly, urinary MMP-9 levels were elevated not only in patients with diabetic renal disease but also in their fi rst-degree relatives when compared with healthy controls (Zaoui et al 2000) . It has been suggested that increased urinary MMP-2 and MMP-9 activities, but not serum MMP levels, may be sensitive markers of the extent of renal disease in type 1 diabetic patients (Tashiro et al 2004) . Urine MMP-2 concentrations correlated with higher HbA1c levels, longer duration of disease, evidence of renal hyperfi ltration, and the presence of microalbuminuria (Thrailkill et al 2007) .
Another study has shown a signifi cant increase in urinary TIMP-1 in association with urinary albumin and the progress of glomerular diffuse lesions, while no correlation between serum TIMP-1 and urinary TIMP-1 was found (Kanauchi et al 1996) . TIMP-1 was also increased in the urine in a group of nondiabetic patients with chronic renal disease and was correlated with progressive reduction in renal function, but not with proteinuria (Horstrup et al 2002) . In an animal model urinary protein excretion showed a signifi cant positive correlation with glomerular and tubular TIMP-2 protein, and a negative correlation with MMP-2 expression (Han et al 2006) .
Diabetic retinopathy
Increased synthesis of type III collagen (serum PIIINP), refl ecting deposition of matrix and BM connective tissue, has been reported in patients with DPR (Arkkila et al 2001) . While some investigators have found no signifi cant differences of serum carboxy-terminal propeptide of human type I procollagen (PICP) across the differing severity of diabetic retinopathy in type 2 diabetic patients (Inukai et al 2000) , others have actually observed progressively decreased levels of serum PICP, which can result in weakened vascular integrity in subjects with retinopathy (Arkkila et al 2001) .
Diabetic retinopathy is associated with increased concentrations of type IV collagen in serum (Yano et al 1998; Kotajima et al 2001) . Although in the vitreous the NH2-terminal CTGF fragment content was increased in patients with active PDR, suggesting that it may play a pathogenic role or may represent a surrogate marker of CTGF activity in DR (Hinton et al 2004) , the elevated level of plasma CTGF found in the circulation in patients with DR compared with patients without DR seems likely to be due to associated nephropathy rather than to the retinopathy itself (Roestenberg et al 2004) . In addition, no changes in urinary CTGF were noted in DR (Nguyen et al 2006) .
Increased plasma levels of VEGF and Ang II were found in diabetic patients, with the highest VEGF and Ang II levels being seen among patients with pre-proliferative and proliferative retinopathy (Lip et al 2004) . The clinical utility of plasma VEGF levels after photocoagulation has yielded contradictory results (Lip et al 2000; Lip et al 2004) .
Diabetic patients with retinopathy also displayed elevated systemic values of MMP-9 and MMP-9/TIMP-1 ratio when compared with patients without retinopathy. Logistic regression analysis identifi ed diabetes duration fi rstly, and MMP-9 serum levels secondly as signifi cant and independent variables associated with the existence of retinopathy in type 1 diabetic patients who were free of other overt vascular complications (Jacqueminet et al 2006) .
Diabetic cardiomyopathy, heart failure
A strong correlation has been reported between myocardial collagen content and serum concentration of PICP in systemic hypertension (Querejeta et al 2000) . Moreover, serum PICP has been found to be secreted by the heart via the coronary sinus in patients with hypertensive heart disease (Querejeta et al 2004) . Thus, even if these markers could be released from various other tissues in diabetes or hypertension, the measurement of serum collagen degradation products may offer a reasonable evaluation of myocardial ECM changes in diabetes. In a highly selected group of uncomplicated type 2 diabetic patients, parameters of myocardial function were positively correlated with glutathione peroxidase and serum PICP, but not with levels of angiotensin II, aldosterone or endothelin-1 (Gonzalez-Vilchez et al 2005) . Serum propeptide of procollagen type I (PIP) appears an independent predictor of new heart failure episodes, readmission and death and a single serum measurement of PIP may have prognostic value in patients presenting with decompensated heart failure (Ruiz-Ruiz et al 2007) .
In hypertensive subjects, plasma TIMP-1 levels were increased and associated with LVH and LV diastolic impairment in some (Laviades et al 1998; Lindsay et al 2002; Timms et al 2002) but not all studies (Li-Saw-Hee et al 2000) . Treatment of hypertension with ACEI has been shown to decrease TIMP-1 levels (Laviades et al 1998) . Previous studies of small samples of patients with heart failure or LV dilatation have yielded inconsistent results, with both increased and decreased levels of myocardial or serum TIMP-1 being reported. (Li et al 1998; Schwartzkopff et al 2002) . The Framingham Heart Study (Sundstrom et al 2004) has shown that plasma total TIMP-1 is directly related to major CVD risk factors and to echocardiographic indices of LVH, and inversely to systolic dysfunction.
It has also been suggested that elevated TIMP-1 might be a useful noninvasive marker of left ventricular diastolic dysfunction and fibrosis (Lindsay et al 2002) . Serum TIMP-1 concentrations over 500 ng/ml showed good specifi city and positive predictive value for detecting diastolic dysfunction among untreated patients with hypertension (Lindsay et al 2002) . In an asymptomatic population with either diabetes or hypertension, but with no evidence of LV hypertrophy, plasma TIMP-1 negatively correlated with e' (early diastolic velocity at the annulus). This suggests that the higher circulating levels of TIMP-1 may refl ect structural changes within the heart that result in diastolic dysfunction. The correlation was however stronger among the hypertensive patients when compared with the diabetic group, suggesting again that systemic hypertension may mainly mediate the TIMP-1 and diastolic dysfunction link (Tayebjee et al 2005a) .
Increased serum levels of AGEs were associated with heart stiffness in patients with type 1 diabetes, possibly mediated by the cross-linking properties of AGEs (Berg et al 1999) .
Atherosclerosis and arteriosclerosis
Plasma plasminogen activator inhibitor (PAI)-1, a potent inhibitor of fi brinolysis, was elevated in a number of clinical situations that are associated with high incidence of cardiovascular disease (CVD) (obesity, hypertension, type 2 diabetes) (Hoekstra et al 2004) .
Serum 7S-collagen levels in diabetic patients with essential hypertension were signifi cantly higher than in normal subjects, and signifi cantly correlated with systolic blood pressure. Thus it has been suggested that the metabolic alteration of basement membrane occurring in patients with diabetes mellitus may worsen in the presence of high systolic Fibrosis markers in diabetic complications blood pressure (Yano et al 1997) . In hypertensive type 2 diabetic patients there were also noted an imbalance between serum MMP-1 which was decreased, and its tissue inhibitor, TIMP-1 which was not signifi cantly changed compared to controls (Alla et al 2006) .
Diabetic patients with acute coronary syndromes showed increased plasma levels of MMP-9, TIMP-1, and TIMP-2 (Derosa et al 2007) . A high percent of patients with coronary artery disease (CAD) or acute coronary syndromes (ACS) had elevated urine values of MMP-9 and TIMP-1 suggesting that these variables might be a useful marker of atherosclerotic disease (Fitzsimmons et al 2006) . Plasma levels of MMP-9, TIMP-2, but not TIMP-1 were high in patients with stable CAD compared with healthy controls. However, no correlation with severity of CAD or collateralization was found (Tayebjee et al 2005b) .
In patients with premature coronary atherosclerosis, the levels of plasma MMP-9 and TIMP-1 were signifi cantly higher, and the levels of MMP-2, MMP-3, and TIMP-2 were signifi cantly lower than those of controls, with signifi cant positive correlation between plasma MMP-9 levels and lowdensity lipoprotein (LDL)-cholesterol levels, and signifi cant negative correlation between plasma MMP-9 levels and high-density lipoprotein (HDL)-cholesterol levels. TIMP-2 levels were negatively correlated with total cholesterol and LDL-cholesterol levels (Noji et al 2001) .
In patients with CAD the low TGF-β group had a signifi cantly poor prognosis in terms of survival without cardiovascular events and survival without coronary interventions as compared with the high TGF-β group, while other prognoses were comparable between the two groups. These results suggest that lower plasma concentrations of TGF-β may have an adverse prognostic signifi cance in patients with CAD (Tashiro et al 2002) . In another study, plasma TGF-β levels were signifi cantly lower in patients with ischemic heart disease than they were in controls (Tashiro et al 1997) .
Liver fi brosis
The serum glyceraldehyde-derived AGEs level may be a useful biomarker for discriminating NASH from simple steatosis. Moreover, it correlated with adiponectin (Hyogo et al 2007) . Serum hyaluronic acid could identify NAFLD in patients with severe fi brosis in some (Sakugawa et al 2005; Kaneda et al 2006) , but not all studies (Yoneda et al 2007) . Type IV collagen 7 s domain and type IV collagen 7s domain concentrations in the circulation have been identifi ed as potential markers in differentiating between NASH and NAFLD (Sakugawa et al 2005) , and between advanced and mild liver fi brosis (Yoneda et al 2007) . Serum levels of endothelin-1 (ET-1), an infl ammatory and marker of increased endothelial tone, also showed a signifi cant positive correlation with liver fi brosis severity in patients with NASH (Degertekin et al 2007) .
TIMP-1 and MMP-1 levels in serum or peripheral blood mononuclear cells (PBMCs) seem to have some value in assessing liver fi brosis. The combination of serum PDGF-BB, TIMP-1 mRNA and TIMP-1mRNA/MMP-1mRNA ratio in PBMCs was suggested as an effi cient test in screening for the presence of liver fi brosis (Zhang et al 2003) .
Research required in circulating and urinary markers of fi brosis in diabetes
Important issues appear when interpreting levels of the ECM markers and their regulators in blood or urine from diabetic patients. First, it is not yet clear whether the assessment of these markers in biological fl uids provide clinically valuable information of the fi brosis process in the affected organs and whether tissue levels are refl ected accurately in blood or urine. Factors such as the relative contribution of a tissue to a particular circulating marker and also the rate of clearance of the marker from the circulation and its dependence on renal function can have signifi cant effects on its level. Nevertheless, the fact that different therapies impact upon their levels indicates that they may be involved in the pathological process.
A second issue is the presence of conditions that commonly co-exist with diabetes, such as hypertension and/or dyslipidemia, which could also influence the levels of circulating/urinary markers of fi brosis. The differentiation between the contribution of diabetes and other co-morbidities to the total level of ECM markers in blood/urine could therefore be diffi cult to assess. Figure 5 summarizes the main fi ndings of circulating and urinary markers and their regulators and their potential value in diabetes complications. At this time, Type IV collagen and CTGF in plasma and urine hold promise in diabetic renal disease, MMP-9 has promise in acute coronary syndromes as does TIMP-1 and also in myocardial dysfunction.
Longitudinal and large studies in appropriate populations of people with diabetes, will be needed to further investigate the possible clinical value of these and other ECM components and ECM regulators as makers for incipient or progressive diabetes complications. Ideally, such markers in their natural history and after therapy, would show predictive value independent of other common clinical variables such as hypertension, degree of glycemic control, and microalbuminuria. It is envisaged that clinically verifi ed algorithms will be generated where automated plasma or urine measures will aid in the calculation of risk of tissue fi brosis, and related organ dysfunction. It may be that other, tissue specifi c measures such as BNP for the heart or liver function tests for liver fi brosis, will be useful in combination with such ECM markers. Urinary measures do appear to often be independent of circulating levels, although whether such measures have advantage over albuminuria and estimated GFR levels, remains to be determined.
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